Our QMS enables continuous organizational and process improvement by incorporating a set of coordinated activities designed to direct and control quality operations. These activities include:
Our QMS is based upon the standards set forth in Good Clinical Practices (GCP), College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA).
CAP | CAP Accreditation in 2017 |
CLIA | CLIA Certified since 2010 |
GCP | Q2 Solutions maintains a QMS that is compliant to the applicable Good Clinical Practices for clinical and genomic testing conducted. |
NYS | NYS Certified in 2018 |
To ensure data quality, we monitor several QC metrics and incorporate controls during sample processing. These practices are required as part of our CLIA compliant programs. They are also recommended in voluntary genomic data submissions to the FDA and are recognized best practices. Our efforts promote standardization initiatives including the External RNA Control Consortium (ERCC), MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) Consortiums.
Single cell RNA sequencing (scRNA-seq) uncovers tissue heterogeneity by providing gene expression measurements in individual cells within a tissue. A current limitation of scRNA-seq is the...
Next generation sequencing (NGS)-based comprehensive genomic profiling has emerged as a powerful tool for the large-scale detection of genomic changes. TruSight Oncology 500 (TSO500) Assay employs a...
Download this presentation to learn more about a new protocol using Chromium Gene Expression Flex to successfully and reliably conduct single cell RNA sequencing with FFPE tumor biopsy tissues. ...